CS
AXSM icon

Credit Suisse’s Axsome Therapeutics AXSM Stock Holding History

Credit Suisse’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$3.49M Sell
43,721
-362
-0.8% -$30.4K ﹤0.01% 1506
2023
Q4 		$3.51M Sell
44,083
-13,210
-23% -$883K ﹤0.01% 1542
2023
Q3 		$4M Sell
57,293
-3,280
-5% -$245K ﹤0.01% 1393
2023
Q2 		$4.35M Buy
60,573
+20,350
+51% +$1.5M ﹤0.01% 1431
2023
Q1 		$2.48M Sell
40,223
-4,919
-11% -$323K ﹤0.01% 1741
2022
Q4 		$3.48M Sell
45,142
-16,474
-27% -$985K ﹤0.01% 1545
2022
Q3 		$2.75M Buy
61,616
+25,413
+70% +$1.27M ﹤0.01% 1642
2022
Q2 		$1.39M Sell
36,203
-9,956
-22% -$315K ﹤0.01% 2160
2022
Q1 		$1.91M Sell
46,159
-76,084
-62% -$2.36M ﹤0.01% 2114
2021
Q4 		$4.62M Buy
122,243
+23,661
+24% +$871K ﹤0.01% 2084
2021
Q3 		$3.25M Buy
98,582
+64,955
+193% +$2.53M ﹤0.01% 2414
2021
Q2 		$2.27M Sell
33,627
-5,206
-13% -$312K ﹤0.01% 2766
2021
Q1 		$2.2M Buy
38,833
+2,463
+7% +$173K ﹤0.01% 2740
2020
Q4 		$2.96M Buy
36,370
+13,918
+62% +$1.04M ﹤0.01% 2535
2020
Q3 		$1.6M Sell
22,452
-4,696
-17% -$366K ﹤0.01% 2591
2020
Q2 		$2.23M Buy
27,148
+11,368
+72% +$875K ﹤0.01% 2300
2020
Q1 		$928K Sell
15,780
-24,787
-61% -$2.02M ﹤0.01% 2709
2019
Q4 		$4.19M Buy
40,567
+22,245
+121% +$898K ﹤0.01% 2005
2019
Q3 		$371K Sell
18,322
-3,943
-18% -$101K ﹤0.01% 3598
2019
Q2 		$573K Buy
+22,265
New +$446K ﹤0.01% 3315
2017
Q3 		– Sell
-16,953
Closed -$93K – 4173
2017
Q2 		$93K Buy
+16,953
New +$71K ﹤0.01% 3728

Other funds holding AXSM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse's AXSM Position: Q1 2024 in Review

Credit Suisse reduced its Axsome Therapeutics (AXSM) stake by 0.82% in Q1 2024, selling an estimated $30.4K and leaving 43,721 shares worth $3.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1506.

Credit Suisse first reported a position in AXSM in Q2 2017 and has held it in 21 quarters since. The position peaked at $4.62M in Q4 2021. 260 funds tracked by Wall St. Rank hold AXSM as of Q1 2024.

  • Credit Suisse held 43,721 shares of Axsome Therapeutics worth $3.49M as of Q1 2024.
  • Credit Suisse sold 362 Axsome Therapeutics shares in Q1 2024, an estimated $30.4K.
  • Axsome Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1506 holding.
  • Credit Suisse first reported a position in Axsome Therapeutics in Q2 2017 and has held it in 21 quarters since.
  • Credit Suisse's Axsome Therapeutics position peaked at $4.62M in Q4 2021.
  • 260 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.